INDOMETHACIN (indomethacin) by Fresenius Kabi is cyclooxygenase inhibitors [moa]. First approved in 2010.
Drug data last refreshed 2h ago · AI intelligence enriched 3d ago
Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) administered via injection that works by inhibiting cyclooxygenase enzymes to reduce inflammation and pain. It is primarily used for acute inflammatory conditions and patent ductus arteriosus (PDA) closure in premature infants. The injectable formulation provides rapid onset of action for patients requiring parenteral administration.
With LOE approaching and moderate competitive pressure (30), this product is in portfolio defense mode with limited growth opportunities for commercial teams.
Cyclooxygenase Inhibitors
Nonsteroidal Anti-inflammatory Drug
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial)
Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin
Comparative Effectiveness Between Indomethacin and Pancreatic Stenting in the Prevention of Post ERCP Pancreatitis
A Study to Compare 3 Doses of a Hormonal Intra-uterine Device Containing Levonorgestrel and Indomethacin With a Hormonal Intra-uterine Device Containing Only Levonorgestrel to Assess the Effect and Safety of the Combined Components
A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy
Worked on INDOMETHACIN at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indomethacin represents a mature, generic-vulnerable product with limited growth runway, making it a challenging assignment for career advancement-focused professionals. Positions on this product are best suited for specialists in portfolio management, generic defense strategies, or niche market development rather than growth-oriented career tracks.